Margaret Lowenstein

Margaret Lowenstein

Auto-generated profile, based on publicly available information

Margaret Lowenstein

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
MLMargaret Lowenstein
Margaret Lowenstein
AKAustin Kilaru
Austin Kilaru
JPJeanmarie Perrone
Jeanmarie Perrone
JHJessica Hemmons
Jessica Hemmons
DADina Abdel-Rahman
Dina Abdel-Rahman
MDM. Kit Delgado
M. Kit Delgado

23 December 2021 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
MLMargaret Lowenstein
Margaret Lowenstein
JPJeanmarie Perrone
Jeanmarie Perrone
RXRuiying A. Xiong
Ruiying A. Xiong
CSChristopher K. Snider
Christopher K. Snider
NONicole O’dOnnell
Nicole O’dOnnell
MDM. Kit Delgado
M. Kit Delgado

1 July 2019 in Lung Cancer
Verified
Journal Article
Closed access
MLMargaret Lowenstein
Margaret Lowenstein
MVMaya Vijayaraghavan
Maya Vijayaraghavan
NBNancy J. Burke
Nancy J. Burke
LKLeah Karliner
Leah Karliner
SWSunny Wang
Sunny Wang
CKCelia P. Kaplan
Celia P. Kaplan

10 October 2019 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
MLMargaret Lowenstein
Margaret Lowenstein
EHErik Hossain
Erik Hossain
WYWei Yang
Wei Yang
DGDavid Grande
David Grande
JPJeanmarie Perrone
Jeanmarie Perrone
MDM. Kit Delgado
M. Kit Delgado

28 September 2021 in SSM - Qualitative Research in Health
Verified
Journal Article
Open access
SAShoshana V. Aronowitz
Shoshana V. Aronowitz
EEEden Engel-Rebitzer
Eden Engel-Rebitzer
MLMargaret Lowenstein
Margaret Lowenstein
ZMZachary Meisel
Zachary Meisel
EAEvan Anderson
Evan Anderson
ESEugenia South
Eugenia South
The COVID-19 pandemic and ensuing service delivery interruptions had serious impacts on people who use drugs (PWUD) and people experiencing homelessness, including instability in the drug supply, decreased access to substance use disorder (SUD) treatment and harm reduction supplies, increased substance use and relapse due to stress and isolation, inability to properly isolate and quarantine without stable housing, and risk of COVID-19 spread in congregate living spaces. At the same time, many have noted a potential opportunity for rapid change in health, housing, and drug policy despite previous stagnation—referred to as a “punctuated equilibrium” by Baumgartner and Jones—in response to the pandemic. The pandemic forced some important policy interventions in the United States at both national and local levels, including eviction moratoriums and loosening of drug policy related to substance use treatment. However, to what extent some of these changes will be sustained past the current COVID-19 crisis is still unclear, as is how drug and housing related policy shifts have impacted the work of frontline overdose prevention, substance use treatment, and homelessness advocacy workers. In this qualitative study, we used semi-structured interviews to assess how Philadelphia’s harm reduction advocates, community organizers, and SUD treatment clinicians have responded to the overdose and homelessness crises during COVID-19, and how they predict the pandemic and ensuing policy changes will impact the future of overdose prevention, harm reduction efforts, and homelessness advocacy. We interviewed 30 eligible participants during July and August 2020. The analysis of these data yielded three themes: 1/“None of it should be new to anybody”: COVID-era issues impacting PWUD and people experiencing homelessness are extensions of existing problems; 2/“An opportunity to actually benefit in some way from this crisis”: Possibility for innovation and improved care for PWUD and people experiencing homelessness; and 3/“Nothing we’ve tried has worked, so we have to be uncomfortable and creative”: The uncertain path forward. Despite the many barriers that participants faced to promoting the health and well-being of marginalized communities during the pandemic, they also believed that the pandemic presented an important opportunity for positive policy change that has the potential to promote drug user health into the future, including a continuation of loosened federal restrictions on substance use disorder treatment, legalization of safe consumption spaces, safe supply of substances, and progressive, creative housing solutions.

15 June 2023 in Annals of Emergency Medicine
Verified
Journal Article
Open access
MLMargaret Lowenstein
Margaret Lowenstein
JPJeanmarie Perrone
Jeanmarie Perrone
RMRachel McFadden
Rachel McFadden
RXRuiying Aria Xiong
Ruiying Aria Xiong
ZMZachary F. Meisel
Zachary F. Meisel
MDMucio Kit Delgado
Mucio Kit Delgado
Emergency department (ED)-initiated buprenorphine improves outcomes in patients with opioid use disorder; however, adoption varies widely. To reduce variability, we implemented a nurse-driven triage screening question in the electronic health record to identify patients with opioid use disorder, followed by targeted electronic health record prompts to measure withdrawal and guide next steps in management, including initiation of treatment. Our objective was to assess the impact of screening implementation in 3 urban, academic EDs. We conducted a quasiexperimental study of opioid use disorder-related ED visits using electronic health record data from January 2020 to June 2022. The triage protocol was implemented in 3 EDs between March and July 2021, and 2 other EDs in the health system served as controls. We evaluated changes in treatment measures over time and used a difference-in-differences analysis to compare outcomes in the 3 intervention EDs with those in the 2 controls. There were 2,462 visits in the intervention hospitals (1,258 in the preperiod and 1,204 in the postperiod) and 731 in the control hospitals (459 in the preperiod and 272 in the postperiod). Patient characteristics within the intervention and control EDs were similar across the time periods. Compared with the control hospitals, the triage protocol was associated with a 17% greater increase in withdrawal assessment, using the Clinical Opioid Withdrawal Scale (COWS) (95% CI 7 to 27). Buprenorphine prescriptions at discharge also increased by 5% (95% CI 0% to 10%), and naloxone prescriptions increased by 12% points (95% CI 1% to 22%) in the intervention EDs relative to controls. An ED triage screening and treatment protocol led to increased assessment and treatment of opioid use disorder. Protocols designed to make screening and treatment the default practice have promise in increasing the implementation of evidence-based treatment ED opioid use disorder care.